UNLABELLED: Recently, the somatostatin receptor subtype 2 (SSTR2) selective antagonist sst2-ANT was determined to have a high affinity for SSTR2. Additionally, 111In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-sst2-ANT showed high uptake in an SSTR2-transfected, tumor-bearing mouse model and suggested that radiolabeled SSTR2 antagonists may be superior to agonists for imaging SSTR2-positive tumors. This report describes the synthesis and evaluation of 64Cu-CB-4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-sst2-ANT (64Cu-CB-TE2A-sst2-ANT) as a PET radiopharmaceutical for the in vivo imaging of SSTR2-positive tumors. METHODS: Receptor-binding studies were performed to determine the dissociation constant of the radiopharmaceutical 64Cu-CB-TE2A-sst2-ANT using AR42J rat pancreatic tumor cell membranes. The internalization of 64Cu-CB-TE2A-sst2-ANT was compared with that of the 64Cu-labeled agonist 64Cu-CB-TE2A-tyrosine3-octreotate (64Cu-CB-TE2A-Y3-TATE) in AR42J cells. Both radiopharmaceuticals were also compared in vivo through biodistribution studies using healthy rats bearing AR42J tumors, and small-animal PET/CT of 64Cu-CB-TE2A-sst2-ANT was performed. RESULTS: The dissociation constant value for the radiopharmaceutical was determined to be 26 +/- 2.4 nM, and the maximum number of binding sites was 23,000 fmol/mg. 64Cu-CB-TE2A-sst2-ANT showed significantly less internalization than did 64Cu-CB-TE2A-Y3-TATE at time points from 15 min to 4 h. Biodistribution studies revealed that the clearance of 64Cu-CB-TE2A-sst2-ANT from the blood was rapid, whereas the clearance of 64Cu-CB-TE2A-sst2-ANT from the liver and kidneys was more modest at all time points. Tumor-to-blood and tumor-to-muscle ratios were determined to be better for 64Cu-CB-TE2A-sst2-ANT than those for 64Cu-CB-TE2A-Y3-TATE at the later time points, although liver and kidney uptake was significantly higher. Small-animal imaging using 64Cu-CB-TE2A-sst2-ANT revealed excellent tumor-to-background contrast at 4 h after injection, and standardized uptake values remained high even after 24 h. CONCLUSION: The PET radiopharmaceutical 64Cu-CB-TE2A-sst2-ANT is an attractive agent, worthy of future study as a PET radiopharmaceutical for the imaging of somatostatin receptor-positive tumors.
UNLABELLED: Recently, the somatostatin receptor subtype 2 (SSTR2) selective antagonist sst2-ANT was determined to have a high affinity for SSTR2. Additionally, 111In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-sst2-ANT showed high uptake in an SSTR2-transfected, tumor-bearing mouse model and suggested that radiolabeled SSTR2 antagonists may be superior to agonists for imaging SSTR2-positive tumors. This report describes the synthesis and evaluation of 64Cu-CB-4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-sst2-ANT (64Cu-CB-TE2A-sst2-ANT) as a PET radiopharmaceutical for the in vivo imaging of SSTR2-positive tumors. METHODS: Receptor-binding studies were performed to determine the dissociation constant of the radiopharmaceutical 64Cu-CB-TE2A-sst2-ANT using AR42J ratpancreatic tumor cell membranes. The internalization of 64Cu-CB-TE2A-sst2-ANT was compared with that of the 64Cu-labeled agonist 64Cu-CB-TE2A-tyrosine3-octreotate (64Cu-CB-TE2A-Y3-TATE) in AR42J cells. Both radiopharmaceuticals were also compared in vivo through biodistribution studies using healthy rats bearing AR42J tumors, and small-animal PET/CT of 64Cu-CB-TE2A-sst2-ANT was performed. RESULTS: The dissociation constant value for the radiopharmaceutical was determined to be 26 +/- 2.4 nM, and the maximum number of binding sites was 23,000 fmol/mg. 64Cu-CB-TE2A-sst2-ANT showed significantly less internalization than did 64Cu-CB-TE2A-Y3-TATE at time points from 15 min to 4 h. Biodistribution studies revealed that the clearance of 64Cu-CB-TE2A-sst2-ANT from the blood was rapid, whereas the clearance of 64Cu-CB-TE2A-sst2-ANT from the liver and kidneys was more modest at all time points. Tumor-to-blood and tumor-to-muscle ratios were determined to be better for 64Cu-CB-TE2A-sst2-ANT than those for 64Cu-CB-TE2A-Y3-TATE at the later time points, although liver and kidney uptake was significantly higher. Small-animal imaging using 64Cu-CB-TE2A-sst2-ANT revealed excellent tumor-to-background contrast at 4 h after injection, and standardized uptake values remained high even after 24 h. CONCLUSION: The PET radiopharmaceutical 64Cu-CB-TE2A-sst2-ANT is an attractive agent, worthy of future study as a PET radiopharmaceutical for the imaging of somatostatin receptor-positive tumors.
Authors: Samuel Achilefu; Hermo N Jimenez; Richard B Dorshow; Joseph E Bugaj; Elizabeth G Webb; R Randy Wilhelm; Raghavan Rajagopalan; Jill Johler; Jack L Erion Journal: J Med Chem Date: 2002-05-09 Impact factor: 7.446
Authors: H Akizawa; Y Arano; M Mifune; A Iwado; Y Saito; T Mukai; T Uehara; M Ono; Y Fujioka; K Ogawa; Y Kiso; H Saji Journal: Nucl Med Biol Date: 2001-10 Impact factor: 2.408
Authors: C J Anderson; F Dehdashti; P D Cutler; S W Schwarz; R Laforest; L A Bass; J S Lewis; D W McCarthy Journal: J Nucl Med Date: 2001-02 Impact factor: 10.057
Authors: Eva Hofsli; Liv Thommesen; Kristin Nørsett; Sture Falkmer; Unni Syversen; Arne Sandvik; Astrid Laegreid Journal: Mol Cell Endocrinol Date: 2002-08-30 Impact factor: 4.102
Authors: Mihaela Ginj; Hanwen Zhang; Klaus-Peter Eisenwiener; Damian Wild; Stefan Schulz; Hans Rink; Renzo Cescato; Jean Claude Reubi; Helmut R Maecke Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: C Andrew Boswell; Xiankai Sun; Weijun Niu; Gary R Weisman; Edward H Wong; Arnold L Rheingold; Carolyn J Anderson Journal: J Med Chem Date: 2004-03-11 Impact factor: 7.446
Authors: Mu Wang; Amy L Caruano; Michael R Lewis; Laura A Meyer; Robert P VanderWaal; Carolyn J Anderson Journal: Cancer Res Date: 2003-10-15 Impact factor: 12.701
Authors: Jessie R Nedrow; Alexander G White; Jalpa Modi; Kim Nguyen; Albert J Chang; Carolyn J Anderson Journal: Mol Imaging Date: 2014 Impact factor: 4.488
Authors: Senthil R Kumar; Fabio A Gallazzi; Riccardo Ferdani; Carolyn J Anderson; Thomas P Quinn; Susan L Deutscher Journal: Cancer Biother Radiopharm Date: 2010-12 Impact factor: 3.099
Authors: Prasant K Nanda; Stephanie R Lane; Lauren B Retzloff; Usha S Pandey; Charles Jeffrey Smith Journal: Curr Opin Endocrinol Diabetes Obes Date: 2010-02 Impact factor: 3.243